ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-17.58%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$221M
AUM Growth
+$221M
(-29%)
Cap. Flow
-$29.6M
Cap. Flow
% of AUM
-13.42%
Top 10 Holdings %
Top 10 Hldgs %
60.19%
Holding
73
New
20
Increased
14
Reduced
17
Closed
20
Top Buys
| 1 |
Sanofi
SNY
|
$17.9M |
| 2 |
Pfizer
PFE
|
$16.7M |
| 3 |
Hologic
HOLX
|
$16.6M |
| 4 |
SI-BONE Inc
SIBN
|
$10.2M |
| 5 |
Johnson & Johnson
JNJ
|
$6.36M |
Top Sells
| 1 |
Cencora
COR
|
$18.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
$14.7M |
| 3 |
Labcorp
LH
|
$10.3M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$10.3M |
| 5 |
Elevance Health
ELV
|
$8.78M |
Sector Composition
| 1 | Healthcare | 89.6% |
| 2 | Industrials | 2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sanofi
SNY
$121B
| $17.9M | 8.12% | +409,961 | New | +$17.9M |
|
|
2
Pfizer
PFE
$141B
| $16.7M | 7.55% | +510,150 | New | +$16.7M |
|
|
3
Hologic
HOLX
$14.9B
| $16.6M | 7.53% | +473,667 | New | +$16.6M |
|
|
4
SI-BONE Inc
SIBN
$719M
| $15.8M | 7.16% | 1,322,344 +851,915 | +181% | +$10.2M |
|
|
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $15.7M | 7.12% | 1,695,888 +477,859 | +39% | +$4.42M |
|
6
Cigna
CI
$80.3B
| $12.7M | 5.74% | 71,428 -9,311 | -12% | -$1.65M |
|
|
7
Elevance Health
ELV
$71.8B
| $9.84M | 4.46% | 43,351 -38,692 | -47% | -$8.78M |
|
8
Zimmer Biomet
ZBH
$21B
| $9.51M | 4.31% | 94,096 -42,068 | -31% | -$4.25M |
|
9
Zoetis
ZTS
$69.3B
| $8.85M | 4.01% | 75,222 +35,025 | +87% | +$4.12M |
|
|
10
Bristol-Myers Squibb
BMY
$96B
| $7.63M | 3.46% | 136,925 -264,509 | -66% | -$14.7M |
|
11
Becton Dickinson
BDX
$55.3B
| $7.12M | 3.23% | 31,000 -26,131 | -46% | -$6M |
|
|
12
Johnson & Johnson
JNJ
$427B
| $6.36M | 2.88% | +48,491 | New | +$6.36M |
|
13
McKesson
MCK
$85.4B
| $4.92M | 2.23% | 36,396 +26,000 | +250% | +$3.52M |
|
|
RCM
14
DELISTED
R1 RCM Inc. Common Stock
RCM
| $4.41M | 2% | 484,801 +238,772 | +97% | +$2.17M |
|
15
Encompass Health
EHC
$12.3B
| $3.56M | 1.61% | 55,614 -107,478 | -66% | -$6.88M |
|
16
AdaptHealth
AHCO
$1.28B
| $3.53M | 1.6% | 220,896 +53,038 | +32% | +$849K |
|
|
17
Labcorp
LH
$23.1B
| $3.33M | 1.51% | 26,344 -81,699 | -76% | -$10.3M |
|
|
PRAH
18
DELISTED
PRA Health Sciences, Inc.
PRAH
| $3.22M | 1.46% | 38,817 -20,166 | -34% | -$1.67M |
|
19
Avantor
AVTR
$9.18B
| $3.12M | 1.41% | +249,382 | New | +$3.12M |
|
20
Prothena Corp
PRTA
$441M
| $2.74M | 1.24% | 255,949 +145,814 | +132% | +$1.56M |
|
21
Aclaris Therapeutics
ACRS
$209M
| $2.72M | 1.23% | 2,619,187 +564,118 | +27% | +$587K |
|
22
Amgen
AMGN
$155B
| $2.68M | 1.21% | +13,193 | New | +$2.68M |
|
|
HRC
23
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $2.64M | 1.2% | 26,240 -39,603 | -60% | -$3.98M |
|
24
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.42M | 1.1% | +28,599 | New | +$2.42M |
|
25
Takeda Pharmaceutical
TAK
$47.3B
| $2.37M | 1.07% | +156,120 | New | +$2.37M |
|